Circio

Circio's mission is to establish its circVec platform as a new gold-standard for nucleic acid and viral therapeutics by leveraging the inherent stability of circular RNA to drive enhanced and durable protein expression. The company has generated compelling preclinical data showing up to 15-fold enhanced and 70-fold more durable expression versus linear mRNA, and is actively pursuing partnerships and internal development across gene therapy, cell therapy, and vaccines. Its strategy involves advancing the circVec platform through its Swedish R&D subsidiary while out-licensing its clinical-stage oncology asset TG01 to external collaborators for further development.

circVec: A proprietary modular genetic cassette platform designed for efficient intracellular biogenesis of multifunctional circular RNA (circRNA) from DNA or viral vectors, enabling significantly enhanced and more durable protein expression compared to linear mRNA systems.

Circio operates in the nascent but competitive circRNA therapeutics space, facing well-funded peers like Laronde and Orna. Its key differentiation is the circVec approach—using circRNA as an intracellular expression system within vectors—rather than delivering synthetic circRNA. It also competes indirectly with other gene therapy enhancement technologies.